Mechanism of action of giritinib

Gilitinib is an oral small molecule drug that is a tyrosine kinase inhibitor and is mainly used to treat FLT3 mutation-positive acute myeloid leukemia (AML). Understanding the mechanism of action of giritinib is critical to understanding its effectiveness in the treatment of AML.

The main mechanism of action of giritinib is as follows:

1.Inhibition ofFLT3receptor activation:FLT3 is a tyrosine kinase receptor that is frequently mutated in AML. These mutations can lead to sustained activation of the FLT3 receptor, thereby promoting the growth and proliferation of AML cells. Giritinib blocks this growth signaling pathway by inhibiting the activation of the FLT3 receptor, thereby inhibiting the proliferation of AML cells.

2.Induction of apoptosis: In addition to inhibiting FLT3 receptor activation, giritinib can also induce AML apoptosis (programmed death). Apoptosis is an important cellular physiological process that helps eliminate abnormal cells and maintain the normal structure and function of tissues. By inducing apoptosis inAML cells, giritinib can reduce the number of abnormal cells, thereby reducing the symptoms and progression of the disease.

3.Blocking cell signaling pathways: In addition to acting directly on theFLT3 receptor, giritinib may also work by affecting other signaling pathways related to cell growth and survival. For example, it may affect signaling pathways such as PI3K/Akt and MAPK, further inhibiting the proliferation and survival of AML cells.

4.Reversal of drug resistance: SomeAML patients may develop resistance to traditional chemotherapy drugs, resulting in poor treatment efficacy. As a targeted therapy, giritinib can reverse some drug resistance and improve treatment efficacy.

In summary, giritinib has a broad and effective inhibitory effect on AML cells by inhibiting FLT3 receptor activation, inducing apoptosis, blocking cell signaling pathways, and reversing drug resistance. This makes giritinib one of the important drugs for the treatment of FLT3 mutation-positive AML, providing an effective treatment option for patients.